AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 192 min read$CAMP

Camp4 Therapeutics (NASDAQ: CAMP) backer sees stake diluted after new share sales

Polaris-affiliated funds and individuals updated their ownership in Camp4 Therapeutics (CAMP) common stock, reporting a lower percentage due to dilution from new share sales. Polaris Management Co. VII now owns 4.8% (3,023,161 shares), while board member Amir Nashat owns 6.3% (3,932,251 shares). The amendment reflects changes since the prior filing.

Original reporting
stocktitan.net
Published Aug 19, 2026, 11:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:54 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$CAMP
Bearish
medium confidence
Mentioned
$CAMP
Relevance
5/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CAMPBearishLow
01

Why it matters

Ownership dilution may slightly depress CAMP share price but also provides capital for development.

02

Market read

The filing updates ownership percentages, a modest but notable event for CAMP shareholders.

03

What to watch

Potential capital raised from share sales may fund pipeline progress.

Relevance 5/10Novelty 7/10Timing: filing disclosed Aug 12, 2026

Background

Camp4 Therapeutics filed an amended Schedule 13D/A reflecting diluted Polaris stake after recent share issuances.

Company-level read

Ticker impact

$CAMPBearishMedium confidence
Context

Amended Schedule 13D/A shows Polaris backer ownership diluted to 4.8% after Camp4 issued additional shares.

Expected impact

Modest downside risk as investors reassess ownership concentration.

Evidence & confidence

Stake reduction signals increased float; limited scale suggests limited price move.

Market effects

Sector

May raise concerns about ownership concentration in biotech small-caps.

Regional

Primarily affects US microcap investors.

Global

Limited, confined to niche biotech investors.

Counterpoint

What could challenge this read

Dilution could attract new investors seeking lower insider control.

Key entities

  • Company
    Camp4 Therapeutics

    Biotech firm listed on NASDAQ (CAMP).

  • Investor
    Polaris Management Co. VII

    Backer holding ~4.8% after dilution.

  • Board Member
    Amir Nashat

    Beneficial owner of ~6.3% via Polaris entities.

Read at source← All news

Related articles

AUG 17
$CAMPMedAI 8/10

CAMP4 Q2 Net Loss Widens; On Track To Advance CMP-002 Into Phase 1/2 Trial In Q4 2026

CAMP4 Therapeutics (CAMP) reported Q2 2026 net loss of $33.5M, or $0.58/share, versus $12.6M, or $0.62/share, a year earlier. The wider loss was mainly due to a $20.9M non-cash derivative fair value change. R&D rose to $10.8M. CAMP4 received Australia and Argentina clearance for a Phase 1/2 CMP-002 trial, expected to start in Q4 2026, and raised $50.1M, extending runway to end-2028.

rttnews.com4 min
AUG 13
$CAMPMed

Camp4 Therapeutics Corp (CAMP): Results of Operations and Financial Condition

Camp4 Therapeutics Corp (CAMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth qua

SEC EDGAR 8-K4 min
AUG 28
$MAIRMedAI 8/10

Billionaire Tycoon Ernesto Bertarelli Buys $219 Million in Madison Air Solutions Shares. What Does This Mean for Investors?

Billionaire Ernesto Bertarelli indirectly purchased 8.8 million shares of Madison Air Solutions (MAIR) at $24.97 per share, totaling $219 million. The acquisition was made through K.C. Armada, LP, bringing his indirect ownership to 11% of the company. MAIR's stock closed at $28.51, a 14% premium over the purchase price. The company has a market cap of $14.3 billion and expects 18% revenue growth this fiscal year.

fool.com2 min
AUG 28
$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

investing.com2 min